Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy

被引:27
作者
Eggert, Martin [1 ,2 ]
Goertsches, Robert [3 ]
Seeck, Ulrike [1 ,2 ]
Dilk, Silvia [3 ]
Neeck, Gunther [1 ,2 ]
Zettl, Uwe K. [3 ]
机构
[1] Rostock Clin S, Dept Internal Med, D-18059 Rostock, Germany
[2] Rostock Clin S, Ctr Rheumatol, D-18059 Rostock, Germany
[3] Univ Rostock, Neurol Clin, D-18147 Rostock, Germany
关键词
multiple sclerosis; blood lymphocytes; NF-kappa B; glucocorticoid pulse therapy;
D O I
10.1016/j.jns.2007.08.026
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Nuclear factor-kappa B activity was analyzed in multiple sclerosis (MS) patients during the course of a methylprednisolone pulse therapy. Molecular effects were evaluated using lymphocytes derived from 20 MS patients before and after therapy and 24 healthy individuals. All patients responded to treatment clinically. The mean level of DNA-binding p65 in MS was proportionate to that of healthy controls, but was significantly decreased directly after therapy whereas the level of DNA-binding p50 was significantly elevated prior to therapy and remained unchanged. In summary, pulse therapy resulted in a decreased level of activated p65 NF-kappa B subunits leading to decreased levels of transcriptionally active pro-inflammatory NF-kappa B. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 37 条
[1]   Glucocorticosteroid therapy for multiple sclerosis: A critical review [J].
Andersson, PB ;
Goodkin, DE .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 160 (01) :16-25
[2]   IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS [J].
AUPHAN, N ;
DIDONATO, JA ;
ROSETTE, C ;
HELMBERG, A ;
KARIN, M .
SCIENCE, 1995, 270 (5234) :286-290
[3]   The NF-κB pathway as a potential target for autoimmune disease therapy [J].
Bacher, S ;
Schmitz, ML .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (23) :2827-2837
[4]  
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[5]  
Bassetti C, 2006, NERVENARZT, V77, P1506, DOI 10.1007/s00115-006-2220-x
[6]   GENE-REGULATION BY STEROID-HORMONES [J].
BEATO, M .
CELL, 1989, 56 (03) :335-344
[7]   A RANDOMIZED, CONTROLLED TRIAL OF CORTICOSTEROIDS IN THE TREATMENT OF ACUTE OPTIC NEURITIS [J].
BECK, RW ;
CLEARY, PA ;
ANDERSON, MM ;
KELTNER, JL ;
SHULTS, WT ;
KAUFMAN, DI ;
BUCKLEY, EG ;
CORBETT, JJ ;
KUPERSMITH, MJ ;
MILLER, NR ;
SAVINO, PJ ;
GUY, JR ;
TROBE, JD ;
MCCRARY, JA ;
SMITH, CH ;
CHROUSOS, GA ;
THOMPSON, HS ;
KATZ, BJ ;
BRODSKY, MC ;
GOODWIN, JA ;
ATWELL, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (09) :581-588
[8]  
Büttner U, 1999, NERVENARZT, V70, P371
[9]   NEGATIVE CROSS-TALK BETWEEN RELA AND THE GLUCOCORTICOID RECEPTOR - A POSSIBLE MECHANISM FOR THE ANTIINFLAMMATORY ACTION OF GLUCOCORTICOIDS [J].
CALDENHOVEN, E ;
LIDEN, J ;
WISSINK, S ;
VANDESTOLPE, A ;
RAAIJMAKERS, J ;
KOENDERMAN, L ;
OKRET, S ;
GUSTAFSSON, JA ;
VANDERSAAG, PT .
MOLECULAR ENDOCRINOLOGY, 1995, 9 (04) :401-412
[10]   DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN PATIENTS WITH CHRONIC PROGRESSIVE FORM OF MULTIPLE-SCLEROSIS [J].
CAZZATO, G ;
MESIANO, T ;
ANTONELLO, R ;
MONTI, F ;
CARRARO, N ;
TORRE, P ;
BOSCO, A ;
CARGNELUTTI, D .
EUROPEAN NEUROLOGY, 1995, 35 (04) :193-198